COMPANY

Molecular Targeting Technologies, Inc.

HQ: West Chester, PA source · mtarget.com ↗ · Mid-Atlantic

Location: West Chester, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: rabies ovarian cancer breast cancer Neuroendocrine Tumors Acute Coronary Syndrome cutaneous leishmaniasis myocardial infarction 177Lu-DOTA-EB-TATE

2Trials (company is sponsor)48NIH grants

Funding and NIH signals

NIH award NIH awarded $638K (NIH grant 1R01CA299133-01, new, notice Aug 24, 2026). NIH RePORTER 1R01CA299133-01 (Aug 24, 2026)
Evidence (1 event)
- Aug 24, 2026 · NIH RePORTER 1R01CA299133-01
  Organization: MOLECULAR TARGETING TECHNOLOGIES, INC.; City/State: WEST CHESTER, PA; Project number: 1R01CA299133-01; Activity code: R01; Fiscal year: 2026; Award notice date: 2026-08-24; FY total cost (award amount): 637529; Administering IC: National Cancer Institute; Project title: Targeted radionuclide therapy for non-small cell lung cancer with Lu-177 EBRGD; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Aug 24, 2026 Grant Government grant — NIH R01: $637,529 (annual award, as published), announced Aug 24, 2026. Agency: NIH/NCI. Source: government award database. source ↗
Jun 18, 2022 Trial start Phase 1: 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors source ↗
2008-10 Trial start Phase 2: Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients. source ↗

Funding

Last 2 years.

Aug 24, 2026 Government grant — NIH R01: $637,529 (annual award, as published), announced Aug 24, 2026. Agency: NIH/NCI. Source: government award database. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT05475210	177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors	Phase 1	Unknown status (ClinicalTrials.gov)	Jun 18, 2022	Dec 31, 2024 (estimated)
NCT00614354	Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients.	Phase 2	Completed	2008-10	2010-09 (actual)

NIH awards 48

Annual award amounts. Total $19.3M.

Jul 31, 2023 NIH award 5R44CA275434-02 FY2023: $999,432 awarded for that fiscal year; activity R44 (SBIR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Instantaneous Tumor source ↗
Jan 31, 2023 NIH award 1R41HL167303-01 FY2023: $299,890 awarded for that fiscal year; activity R41 (STTR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Phosphatidylserine-b source ↗
Aug 10, 2022 NIH award 1R44CA275434-01 FY2022: $999,389 awarded for that fiscal year; activity R44 (SBIR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Instantaneous Tumor source ↗
Jan 12, 2022 NIH award 5R01CA226531-04 FY2022: $500,963 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PAK, KOON Y; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Early Prediction of T source ↗
Apr 23, 2021 NIH award 5R01CA226531-03 FY2021: $514,387 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PAK, KOON Y; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Early Prediction of T source ↗
Feb 3, 2020 NIH award 5R01CA226531-02 FY2020: $570,747 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PAK, KOON Y; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Early Prediction of T source ↗
Feb 8, 2019 NIH award 3R43CA224579-01A1S1 FY2019: $23,808 awarded for that fiscal year; activity R43 (SBIR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Sprayable, Prompt source ↗
Jan 30, 2019 NIH award 1R01CA226531-01A1 FY2019: $585,113 awarded for that fiscal year; activity R01 (OTHER_NIH); PI PAK, KOON Y; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Early Prediction of source ↗
Apr 9, 2018 NIH award 1R43CA224579-01A1 FY2018: $229,603 awarded for that fiscal year; activity R43 (SBIR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Sprayable, Prompt source ↗
2018 NIH contract (government contract; not a grant and not an investment round) 261201700037C-3-0-2 FY2018: $50,007 awarded for that fiscal year; activity N43 (OTHER_NIH); PI GRAY, BRIAN D.; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTE source ↗
Jul 14, 2017 NIH award 1R43AI133620-01 FY2017: $214,174 awarded for that fiscal year; activity R43 (SBIR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Topical Drug Treatme source ↗
2017 NIH contract (government contract; not a grant and not an investment round) 261201700037C-0-0-2 FY2017: $299,989 awarded for that fiscal year; activity N43 (OTHER_NIH); PI GRAY, BRIAN D.; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHEST source ↗
Mar 23, 2015 NIH award 1R43HL127892-01 FY2015: $224,819 awarded for that fiscal year; activity R43 (SBIR); PI MATTIS, JEFFREY A.; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. A PE-specific SPECT source ↗
May 21, 2014 NIH award 5R42AI073064-05 FY2014: $833,079 awarded for that fiscal year; activity R42 (STTR); PI SCHNELL, MATTHIAS JOHANNES; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. A novel vac source ↗
2014 NIH contract (government contract; not a grant and not an investment round) 268201400043C-0-0-1 FY2014: $222,581 awarded for that fiscal year; activity N43 (OTHER_NIH); PI MATTIS, JEFFREY; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHES source ↗
Aug 5, 2013 NIH award 1R43GM108470-01 FY2013: $219,935 awarded for that fiscal year; activity R43 (SBIR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Multicolor Cell Memb source ↗
May 14, 2013 NIH award 5R42AI073064-04 FY2013: $858,482 awarded for that fiscal year; activity R42 (STTR); PI SCHNELL, MATTHIAS JOHANNES; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. A novel vac source ↗
Jul 12, 2012 NIH award 5R42AI081334-03 FY2012: $415,582 awarded for that fiscal year; activity R42 (STTR); PI MCGETTIGAN, JAMES P; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Human Rabies Virus source ↗
Jun 21, 2012 NIH award 2R42AI073064-03A1 FY2012: $817,599 awarded for that fiscal year; activity R42 (STTR); PI SCHNELL, MATTHIAS JOHANNES; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. A novel v source ↗
Jun 15, 2012 NIH award 1R43AI094709-01A1 FY2012: $224,438 awarded for that fiscal year; activity R43 (SBIR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Anionic Phospholip source ↗
Aug 9, 2011 NIH award 2R42AI081334-02 FY2011: $414,018 awarded for that fiscal year; activity R42 (STTR); PI MCGETTIGAN, JAMES P; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Human Rabies Virus source ↗
Aug 18, 2010 NIH award 5R44CA136306-03 FY2010: $376,588 awarded for that fiscal year; activity R44 (SBIR); PI PAK, KOON Y; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Radiohybridization Imaging source ↗
Jul 12, 2010 NIH award 1R43GM093417-01 FY2010: $196,224 awarded for that fiscal year; activity R43 (SBIR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Dual Modality Labels source ↗
Aug 24, 2009 NIH award 5R44CA136306-02 FY2009: $342,141 awarded for that fiscal year; activity R44 (SBIR); PI PAK, KOON Y; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Radiohybridization Imaging source ↗
Jul 15, 2009 NIH award 1R43EB009266-01 FY2009: $176,838 awarded for that fiscal year; activity R43 (SBIR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Superior Near-IR Dye source ↗
May 22, 2009 NIH award 1R43EB009591-01 FY2009: $193,511 awarded for that fiscal year; activity R43 (SBIR); PI GRAY, BRIAN D; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Bright and Stable Near-I source ↗
Mar 28, 2009 NIH award 1R41AI081334-01A1 FY2009: $162,433 awarded for that fiscal year; activity R41 (STTR); PI MCGETTIGAN, JAMES P; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Human Rabies Vir source ↗
Feb 25, 2009 NIH award 5R44HL062770-06 FY2009: $679,501 awarded for that fiscal year; activity R44 (SBIR); PI PAK, KOON Y; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Tc-99m Glucarate for chest source ↗
Feb 23, 2009 NIH award 5R41AI073064-02 FY2009: $336,589 awarded for that fiscal year; activity R41 (STTR); PI SCHNELL, MATTHIAS JOHANNES; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. A novel vac source ↗
Aug 18, 2008 NIH award 5R44MH079805-06 FY2008: $575,955 awarded for that fiscal year; activity R44 (SBIR); PI GRAY, BRIAN DAVID; recipient as written: MOLECULAR TARGETING TECHNOLOGIES, INC., WEST CHESTER, PA. Optimizing Tracers F source ↗